Axsome Therapeutics, Inc. (AXSM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 50 | 271 | 386 | 638 | 777 | 963 |
| Operating profit | $m | -169 | -189 | ||||||
| Net profit | $m | -103 | -130 | -187 | -239 | -287 | -183 | -192 | -136 |
| EPS reported | $ | -3.68 | -3.75 | ||||||
| Operating cashflow per share | $ | -1.88 | -1.38 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -1.89 | -1.39 | ||||||
| Free cash flow | $m | -94 | -71 | ||||||
| Net debt | $m | -109 | -132 | ||||||
| Book value equity | $m | 88 | 83 | ||||||
| Book value per share | $ | 1.77 | 1.62 | ||||||
| Number of shares | m | 49.75 | 51.5 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 102.90 | 109.07 | ||||||
| P/S LTM | x | 14.23 | 11.70 | ||||||
| P/FCF LTM | x | -96.78 | -127.27 | ||||||
| EV/EBITDA LTM | x | -53.57 | -50.08 | ||||||
| EV/Sales LTM | x | 14.10 | 13.57 | ||||||
| Earnings Yield LTM | % | -2.02% | -1.80% | ||||||
| FCF Yield | % | -1.03% | -0.79% | ||||||
| Quality | |||||||||
| ROE | % | -207.46% | -255.60% | ||||||
| ROIC | % | -43.95% | -50.73% | ||||||
| Operating margin | % | -26.51% | -24.28% | ||||||
| Gross margin | % | +92.56% | +93.24% | ||||||
| FCF/Sales | % | -14.70% | -9.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +65.55% | +101.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.39 | -0.33 | ||||||
| Net Debt/EBITDA | x | 0.49 | 0.56 | ||||||
| EBIT/Net interest | x | -25.81 | -37.58 | ||||||
| Net debt/market cap | % | +2.35% | +1.77% | ||||||
| Net debt/Equity | x | -1.23 | -1.58 | ||||||
| Gross debt/equity | x | 2.73 | 2.63 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Axsome Therapeutics, Inc. (AXSM)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free